District Court Upholds HSR Rulemaking on Pharmaceutical Patent Licensing Transactions

by Wilson Sonsini Goodrich & Rosati

The transfer of certain patent rights in the pharmaceutical industry will remain subject to the premerger notification rules under the Hart-Scott-Rodino Act (HSR Act) after a federal judge rejected a challenge brought by the Pharmaceutical Research and Manufacturers of America (PhRMA).1 The U.S. District Court for the District of Columbia held that the Federal Trade Commission (FTC) has statutory authority to issue industry-specific rules under the HSR Act, provided that there is a rational basis for the rule and the FTC observes the procedural requirements of the Administrative Procedures Act (APA).


The HSR Act applies to acquisitions of voting securities and assets. Patent licenses have been treated as asset acquisitions by the licensee only if the license is exclusive (i.e., if the license transfers the exclusive right to "make, use, and sell" under the patent, even as against the licensor). Non-exclusive licenses have not been treated as asset acquisitions. Under the "make, use, and sell" approach, which was never codified, a license was not considered sufficiently exclusive and, therefore, not an acquisition of an asset, so long as the licensee retained the right to manufacture under the patents in the United States. In promulgating the new rule, the FTC concluded that the reservation of limited manufacturing rights on the part of the licensor was "no longer adequate in evaluating the reportability of exclusive licenses in the pharmaceutical industry for HSR purposes."2

In August 2012, the FTC proposed a new rule in which a patent license in the pharmaceutical industry will amount to an asset acquisition if "all commercially significant rights" to a patent or part of a patent are conveyed. The FTC defines "all commercially significant rights" as "the exclusive rights to a patent that allow only the recipient of the exclusive patent rights to use the patent in a particular therapeutic area (or specific indication within a therapeutic area)."3 The agency provides little guidance as to what amounts to a transfer of "all commercially significant rights" other than that such rights can be transferred even if the patent holder retains limited manufacturing rights or co-rights. This is the primary effect of the new rule and what distinguishes the new treatment of pharmaceutical patents from the FTC's previous approach. The final rule was promulgated without any changes from the proposed version on November 15, 2013, and became effective on December 16, 2013.

The HSR rules already include several industry-specific exemptions, including exemptions for acquisitions of certain industry-specific assets (e.g., oil and gas reserves) and acquisitions by certain types of persons (e.g., securities underwriters, creditors and insurers, and certain institutional investors). However, this was the first time in the then-37-year history of the HSR Act that a premerger notification requirement singled out a particular industry.

PhRMA's Challenge to the New Rule

A few days before the new rule became effective, PhRMA—an industry group representing biopharmaceutical researchers and biotechnology companies—filed a complaint in federal court arguing that the new rule violated the APA and should be set aside. PhRMA moved for summary judgment, contending that the FTC: (1) lacked statutory authority under the HSR Act to issue an industry-specific rule rather than a rule of general application, (2) failed to establish a rational basis for such an industry-specific rule, and (3) failed to include in the rulemaking record the factual basis for its decision contrary to the procedure required by law. Interestingly, PhRMA only challenged the industry-specific application of the rule but not whether the FTC had exceeded its authority by improperly classifying certain types of patent licenses as asset acquisitions. Thus, even if PhRMA succeeded in its challenge, the FTC may have tried to apply the rule to all industries on remand.

Court Sides with the FTC

In denying PhRMA's motion for summary judgment and granting summary judgment for the FTC, U.S. District Judge Beryl A. Howell agreed with the agency that it was entitled to deference in its interpretation of the HSR Act's grant of authority to promulgate industry-specific rules under the relevant cases addressing promulgation of rules by agencies like the FTC.4 The court found that the rule survives the first step of the administrative deference analysis because the plain language of the HSR Act "does not mandate that the FTC only promulgate rules of general applicability and does not foreclose the FTC's issuance of an industry-specific rule." The court further found that the FTC's construction of the statute is permissible because Congress has not directly spoken on the issue and that it is entitled to deference in construing its powers to "define terms used" in the act and to "prescribe such other rules as may be necessary and appropriate to carry out the purposes" of the act as enabling it to promulgate an industry-specific rule.

Judge Howell also found that the rulemaking was not arbitrary, capricious, or an abuse of discretion because the FTC articulated a rational justification for limiting the new rule to the pharmaceutical industry, including observations that exclusive transfers of patent rights almost solely occur in the pharmaceutical industry and that transfers where the licensor retains limited manufacturing rights or co-rights have become more common for pharmaceutical companies in recent years. The court further found that that the FTC observed the procedure required by law under the APA because it included sufficient factual material in support of its decision in the administrative record and afforded PhRMA a sufficient opportunity to participate in the rulemaking process.


As a result of the district court's decision, the FTC's "all commercially significant rights" test will continue to apply to transfers of patent rights in the pharmaceutical industry. Thus, even if the patent holder retains limited manufacturing rights or co-rights, the transfer of exclusive rights to a pharmaceutical patent will be considered a potentially reportable asset transaction under the HSR Act. The new rule, however, only applies to the pharmaceutical industry. The FTC has not promulgated any rules or published any informal guidance as to whether it will apply the "all commercially significant rights" or "make, use, and sell" approach to other industries. Thus, it remains an open question whether the retention of limited manufacturing rights are sufficient to render an otherwise exclusive license to patents outside the pharmaceutical industry non-exclusive and therefore non-reportable for HSR purposes.

Parties in any industry must take heed when engaging in patent licensing transactions and engage antitrust counsel to determine whether their transaction requires notification under the HSR Act. Violations of the HSR Act, even unintentional ones, can lead to significant consequences, including civil penalties of up to $16,000 per day.

Finally, the district court's decision may not be the final word. PhRMA has up to 60 days to appeal the decision to the U.S. Court of Appeals for the District of Columbia Circuit. Wilson Sonsini Goodrich & Rosati will continue to monitor this case and related developments, including whether the FTC tries to apply the "all commercially significant rights" test to transfers of patent rights in other industries.

1 Pharmaceutical Research and Manufacturers of America v. FTC, No. 13-CV-01974 (D.D.C. May 30, 2014).

2 78 Fed. Reg. 68,705, 68,706 (Nov. 15, 2013).

3 Id. at 68,713

4 Judicial review of agency rulemaking under the APA is judged under the two-part Chevron deference standard. See Chevron U.S.A., Inc. v. Natural Res. Def. Council, Inc., 467 U.S. 837, 842 (1984). The first step of the Chevron analysis asks whether Congress has "directly spoken to the precise question at issue." Id. If yes, the court "must give effect to the unambiguously expressed intent of Congress." Id. at 843. If the statute is silent or ambiguous, then the court must proceed to the second step and defer to the agency's interpretation if it offers "permissible construction of the statute." Id.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Wilson Sonsini Goodrich & Rosati | Attorney Advertising

Written by:

Wilson Sonsini Goodrich & Rosati

Wilson Sonsini Goodrich & Rosati on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.